Onconova Therapeutics Inc. Warrants
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Onconova Therapeutics Inc. Warrants generated cash of -$23,075,000, which is less than the previous year. Cash used in financing activities reached the amount of $19,357,000 last year. Net change in cash is therefore -$3,701,000.
Cash Flow
| 2011 | -14.17M | -241K | 9.78M |
|---|---|---|---|
| 2012 | 1.63M | -279K | 77.46M |
| 2013 | -61.38M | -40.59M | 80.46M |
| 2014 | -57.64M | 39.77M | 1.46M |
| 2015 | -31.23M | 0 | 7.46M |
| 2016 | -15.81M | 0 | 17.42M |
| 2017 | -23.82M | 0 | 6.36M |
| 2018 | -22.69M | 0 | 35.65M |
| 2019 | -20.83M | -55K | 26.64M |
| 2020 | -23.07M | -15K | 19.35M |
ONTXW Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 22.72M | 16.97M | 4.02M | 21.45M | 19.79M | 43.58M | 60.00M | 81.52M | 2.71M | 7.34M |
Operating activities | ||||||||||
Net income | -25.15M | -21.50M | -20.57M | -24.09M | -19.66M | -23.97M | -63.68M | -62.54M | -29.91M | -26.29M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 13K | 14K | 55K | 88K | 96K | 150K | 434K | 446K | 319K | 316K |
Stock-based compensation expense | 369K | 1.04M | 1.14M | 1.71M | 3.92M | 3.78M | 5.06M | 8.01M | 13.84M | 6K |
| Deferred income tax benefit | 369K | 1.04M | 1.14M | 1.71M | 3.92M | 3.78M | 5.06M | 8.01M | 13.84M | 6K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 562K | 232K | -1.45M | 863K | 1.90M | -606K | 317K | -1.80M | -97K | 2.23M |
Cash generated by operating activities | -23.07M | -20.83M | -22.69M | -23.82M | -15.81M | -31.23M | -57.64M | -61.38M | 1.63M | -14.17M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -39.99M | 0 | 0 |
Investments In Property Plant And Equipment | -15K | -55K | 0 | 0 | 0 | 0 | -228K | -609K | -279K | -256K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -15K | -55K | 0 | 0 | 0 | 0 | 39.77M | -40.59M | -279K | -241K |
Financing activities | ||||||||||
Common Stock Issued | 9.06M | 21.75M | 35.06M | 6.36M | 17.42M | 7.46M | 0 | 79.81M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -917K |
Cash used in financing activities | 19.35M | 26.64M | 35.65M | 6.36M | 17.42M | 7.46M | 1.46M | 80.46M | 77.46M | 9.78M |
Net Change In Cash | -3.70M | 5.75M | 12.94M | -17.42M | 1.60M | -23.78M | -16.42M | -21.51M | 78.81M | -4.62M |
Cash at end of period | 19.02M | 22.72M | 16.97M | 4.02M | 21.4M | 19.79M | 43.58M | 60.00M | 81.52M | 2.71M |
| Data source |